Charles River Leverages Virtual Control Groups in GLP Studies
Stocks in this Quantisnow insightHealth Care
Historical context for CRL
Across the 30 sessions after earlier CRL headlines, the stock closed higher 15 times and lower 15 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRL | SPY |
|---|---|---|---|
| Oct 23, 2026 | Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment | +1.7% | -0.5% |
| Oct 13, 2026 | Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development | -0.9% | -0.0% |
| Oct 9, 2026 | Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call | +1.3% | +0.6% |
| Oct 6, 2026 | Charles River and Autolomous Partner to Transform Laboratory Execution Systems | -1.9% | +0.5% |
| Sep 30, 2026 | UBS resumed coverage on Charles River with a new price target | -0.3% | -0.2% |
| Sep 24, 2026 | Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day | +6.2% | -0.1% |
Quantisnow market dataNYSE
CRL
Charles River Laboratories International Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Listed since
- 2000
Get push alerts for CRL
Full CRL profile on Quantisnow Follow CRL and get a push notification the moment its next story breaks.